SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655 Attorney Docket No. Q58513

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (canceled).

2. (canceled).

3. (canceled).

4. (canceled).

5. (canceled).

6. (canceled).

7. (canceled).

8. (canceled).

9. (canceled).

10. (canceled).

11. (canceled).

12. (canceled).

13. (canceled).

14. (canceled).

15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (canceled).

20. (canceled).

(2) 21. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-prostaglandin compound.

(3) 22. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono or dihalogen-prostaglandin compound.

(4) 23. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or di-halogen-prostaglandin compound.

(5) 24. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono or di-fluoro-prostaglandin compound.

(6) 25. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or di-fluoro-prostaglandin compound.

(7) 26. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-20-lower alkyl-prostaglandin compound.

(8) 27. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-20-ethyl-prostaglandin compound.

(9) 28. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxy lower alkyl)-15-keto-prostaglandin compound.

(10) 29. (previously presented): The method of claim 1, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-15-keto-prostaglandin compound.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655 Attorney Docket No. Q58513

(11) 30. (previously presented): The method of claim ~~41~~ 1, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16-mono or di-fluoro prostaglandin compound.

(12) 31. (previously presented): The method of claim ~~41~~ 1, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16-mono or di-fluoro-20-ethyl-prostaglandin compound.

(13) 32. (previously presented): The method of claim ~~41~~ 1, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-di-fluoro-20-ethyl-prostaglandin compound.

(14) 33. (previously presented): The method of claim ~~41~~ 1, wherein the 15-keto prostaglandin compound is a 15-keto-prostaglandin E compound.

(15) 34. (previously presented): The method of claim ~~41~~ 1, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-di-fluoro-20-ethyl-prostaglandin E_1 isopropyl ester.

35. (canceled).

36. (canceled).

37. (canceled).

(16) 38. (previously presented): The method of claim ~~41~~ 1, which comprises administering ophthalmically a composition comprising a 15-keto-prostaglandin compound formulated in a dosage form suitable for ophthalmic administration.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655 Attorney Docket No. Q58513

(17) 39. (previously presented): The method of claim 16, wherein said composition is formulated as eye drops.

40. (canceled).

(1) 41. (previously presented): A method for treating photoretinitis in a subject, which comprises administering an effective amount of a 15-keto prostaglandin compound represented by the following formula (II):



(II)

wherein L and M are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, hydroxy(lower)alkyl or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have one or more double bond;

A is $-CH_2OH$, $-COCH_2OH$, -COOH or its functional derivative;

B is $-CH_2-CH_2-$, -CH=CH- or $-C\equiv C-$;

X_1 and X_2 are hydrogen, lower alkyl or halogen;

R_1 is a divalent saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group;

R_2 is a single bond or lower alkylene; and

R_3 is lower alkyl, lower alkoxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group

to the subject.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655 Attorney Docket No. Q58513

42. (canceled).

(18) 43. (new): A method for treating light induced retinal photic injury in a subject, which comprises administering an effective amount of a 15-keto prostaglandin compound represented by the following formula (II):



(II)

wherein L and M are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, hydroxy(lower)alkyl or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have one or more double bond;

A is $-CH_2OH$, $-COCH_2OH$, -COOH or its functional derivative;

B is $-CH_2-CH_2-$, -CH=CH- or -C≡C-;

X_1 and X_2 are hydrogen, lower alkyl or halogen;

R_1 is a divalent saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group;

R_2 is a single bond or lower alkylene; and

R_3 is lower alkyl, lower alkoxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group

to the subject.